133 related articles for article (PubMed ID: 37598053)
1. Effect of outpatient administration of levosimendan in reducing hospital readmission in patients with heart failure.
Acosta-Armas P; Medina-Gil JM; Martínez-Quintana E
Med Clin (Barc); 2023 Nov; 161(9):403-404. PubMed ID: 37598053
[No Abstract] [Full Text] [Related]
2. Can we believe in levosimendan?
Follath F
Arq Bras Cardiol; 2008 Mar; 90(3):146-7. PubMed ID: 18392391
[No Abstract] [Full Text] [Related]
3. Levosimendan use in several scenarios of acute heart failure.
Tavares M; Andrade AC; Mebazaa A
Arq Bras Cardiol; 2008 Mar; 90(3):211-5. PubMed ID: 18392402
[TBL] [Abstract][Full Text] [Related]
4. Patients with advanced heart failure and the effects of levosimendan.
Song ZZ; Ma J
Am J Cardiol; 2007 Aug; 100(4):742; author reply 742-3. PubMed ID: 17697841
[No Abstract] [Full Text] [Related]
5. Tricuspid valve replacement and levosimendan.
Cicekcioglu F; Parlar AI; Altinay L; Yay K; Katircioglu SF
Gen Thorac Cardiovasc Surg; 2008 Nov; 56(11):559-62. PubMed ID: 19002757
[TBL] [Abstract][Full Text] [Related]
6. Levosimendan for the treatment of acute heart failure syndromes: time to identify subpopulations of responding patients.
Parissis JT; Farmakis D; Bistola V; Adamopoulos S; Kremastinos DT
Am J Cardiol; 2007 Jan; 99(1):146-7. PubMed ID: 17196480
[No Abstract] [Full Text] [Related]
7. A struggle to SURVIVE: to abandon or not to abandon levosimendan?
Butler J; Giamouzis G; Giannakoulas G
Cardiovasc Drugs Ther; 2007 Oct; 21(5):401-2. PubMed ID: 17701453
[No Abstract] [Full Text] [Related]
8. Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure.
Duman D; Palit F; Simsek E; Bilgehan K; Sacide A
Can J Cardiol; 2009 Oct; 25(10):e353-6. PubMed ID: 19812809
[TBL] [Abstract][Full Text] [Related]
9. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
Nieminen MS; Cleland JG; Eha J; Belenkov Y; Kivikko M; Põder P; Sarapohja T
Eur J Heart Fail; 2008 Dec; 10(12):1246-54. PubMed ID: 18945637
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of levosimendan in patients with acute heart failure.
Fedele F; D'Ambrosi A; Bruno N; Caira C; Brasolin B; Mancone M
J Cardiovasc Pharmacol; 2011 Oct; 58(4):363-6. PubMed ID: 21697728
[TBL] [Abstract][Full Text] [Related]
11. [LEVOSIMENDAN--THE FIRST 10 YEARS IN CLINICAL PRACTICE].
Rybka MM; Lobacheva GV
Anesteziol Reanimatol; 2015; 60(5):80-4. PubMed ID: 26852586
[TBL] [Abstract][Full Text] [Related]
12. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE.
Mebazaa A; Nieminen MS; Filippatos GS; Cleland JG; Salon JE; Thakkar R; Padley RJ; Huang B; Cohen-Solal A
Eur J Heart Fail; 2009 Mar; 11(3):304-11. PubMed ID: 19158152
[TBL] [Abstract][Full Text] [Related]
13. Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach.
Giamouzis G; Giannakoulas G; Tsarpalis K; Agha SA; Georgiopoulou V; Kalogeropoulos A; Karvounis H; Butler J
Int J Cardiol; 2008 Aug; 128(1):91-3; author reply 94-6. PubMed ID: 18495268
[No Abstract] [Full Text] [Related]
14. Levosimendan in patients with decompensated heart failure.
Rosa EM; Osório AP; Scopel L
Arq Bras Cardiol; 2008 Aug; 91(2):119. PubMed ID: 18709265
[No Abstract] [Full Text] [Related]
15. Novel biologic mechanisms of levosimendan and its effect on the failing heart.
Parissis JT; Andreadou I; Bistola V; Paraskevaidis I; Filippatos G; Kremastinos DT
Expert Opin Investig Drugs; 2008 Aug; 17(8):1143-50. PubMed ID: 18616411
[TBL] [Abstract][Full Text] [Related]
16. The predictive value of QRS duration in response to levosimendan therapy in patients with decompensated heart failure.
Cetin M; Uçar O; Cicekçioğlu H; Güven Cetin Z; Sahin M; Vasfi Ulusoy F; Aydoğdu S
Acta Cardiol; 2012 Jun; 67(3):317-23. PubMed ID: 22870740
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of levosimendan in patients with chronic heart failure: Does rhythm matter?
Yontar OC; Yilmaz MB; Yalta K; Tandoğan I
Anadolu Kardiyol Derg; 2010 Aug; 10(4):310-6. PubMed ID: 20693125
[TBL] [Abstract][Full Text] [Related]
18. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure.
Lilleberg J; Laine M; Palkama T; Kivikko M; Pohjanjousi P; Kupari M
Eur J Heart Fail; 2007 Jan; 9(1):75-82. PubMed ID: 16829185
[TBL] [Abstract][Full Text] [Related]
19. [Levosimendan. Clinical indications of a new vasoactive substance].
Braun JP; Döpfmer U; Kastrup M; Roots I; Borges A; Schneider M; Dohmen P; Kox W; Spies C
Anaesthesist; 2004 Feb; 53(2):163-7. PubMed ID: 14991194
[TBL] [Abstract][Full Text] [Related]
20. Economic analysis of intermittent intravenous outpatient treatment with levosimendan in advanced heart failure in Spain.
Manito Lorite N; Rubio-Rodríguez D; González Costello J; Díez López C; Enjuanes Grau C; Segovia-Cubero J; Delgado Jimenez JF; Campo Sien C; Rubio-Terrés C; Comín-Colet J; ;
Rev Esp Cardiol (Engl Ed); 2020 May; 73(5):361-367. PubMed ID: 31899185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
